High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure

M Pecherstorfer, I Zimmer-Roth, S Weidinger, K Irsigler, W M Halbmayer, W Ulrich, M Fischer, G Baumgartner

Research output: Journal article (peer-reviewed)Journal article

12 Citations (Scopus)


A kappa light-chain myeloma was diagnosed as the underlying disease in a 52-year-old woman with acute oliguric renal failure. The patient was erroneously treated with high-dose intravenous melphalan (60 mg/m2). Because of this overdose treatment with granulocyte colony-stimulating factor was initiated, but pronounced absolute leukopenia (white blood cell count < 0.5 x 10(9)/l) developed and lasted for 13 days. Following melphalan treatment a continuous increase in urine volume was accompanied by a decrease of serum creatinine and blood urea nitrogen. Within 10 days after the administration of melphalan the patient no longer required hemodialysis. We conclude that high-dose chemotherapy in combination with hematopoietic growth factors should be considered in individual cases with newly diagnosed light-chain nephropathy.

Original languageEnglish
Pages (from-to)522-5
Number of pages4
JournalJournal of Molecular Medicine
Issue number7
Publication statusPublished - Jul 1994
Externally publishedYes


  • Acute Kidney Injury/complications
  • Dose-Response Relationship, Drug
  • Drug Overdose
  • Female
  • Humans
  • Injections, Intravenous
  • Melphalan/administration & dosage
  • Middle Aged
  • Multiple Myeloma/drug therapy
  • Oliguria/drug therapy
  • Renal Dialysis


Dive into the research topics of 'High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure'. Together they form a unique fingerprint.

Cite this